- The Medicines Company
- AstraZeneca
- Portola Pharmaceuticals, Inc.
- Bayer Pharmaceuticals
- Bristol-Myers Squibb Company
- Bochringer Ingelheim Pharmaceuticals, Inc.
- Altimed Pharma Inc.
- Dominion Pharmacal
- Alta Laboratories Ltd
- Novacap
- Shandong Xinhua Pharmaceutical
- Nanjing Pharmaceutical Factory
- Sanis Health Inc
- Syntax Inc.
- Hoffmann La Roche
- Teva
- Sandoz Canada Incorporated
- Phammopcience Inc
- Nu Pharpint
- Mylan Pharmaceuticals
(Note: The list of the major players will be updated with the latest market scenario and trends)
The rising global incidence of diseases transmitted by arthropods, such as dengue, Zika, and Lyme, drives the demand for accurate and accessible testing methods. Heightened awareness of emerging infectious diseases, particularly those transmitted by arthropods, has led to increased investment in research and development of testing methods. Ongoing technological advancements, such as improved PCR techniques, serological assays, and next-generation sequencing, have enhanced the accuracy, sensitivity, and specificity of tests for arthropod-borne viral infections. Increased international travel and population mobility contribute to the spread of arthropod-borne diseases, emphasizing the need for robust testing infrastructure worldwide and propelling the market.
However, some advanced testing methods, like PCR and next-generation sequencing, require specialized equipment, trained personnel, and controlled laboratory environments, which may only be readily available in some healthcare settings. High upfront costs for purchasing and maintaining advanced diagnostic equipment, as well as the need for skilled technicians, can be prohibitive for healthcare facilities, particularly in resource-constrained settings. While testing is crucial, comprehensive prevention strategies, such as vector control and vaccination programs, can sometimes overshadow investments in testing infrastructure, hampering the market.